IM96 CAR-T cell Therapy

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameIM96 CAR-T cell Therapy
Drug Alias NameIM96
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Heat-stable enterotoxin receptor
TargetsHeat-stable enterotoxin receptor
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesImunopharm Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShandong Jinsai Biotechnology Co LtdImunopharm Technology Co LtdBeijing Yimiao Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A